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LESS IS MORE

Gabapentinoid Use in the United States 2002 Through 2015
Gabapentin and pregabalin are the 2 clinically used medications in the gabapentinoid drug class. Pregabalin and gabapentin have both been approved by the US Food and Drug Administration for treatment of partial seizures and postherpetic neuralgia. Gabapentin enacarbil has also been approved for restless legs syndrome, while pregabalin has additional approvals for diabetic peripheral neuropathy, neuropathic pain associated with spinal cord injury, and fibromyalgia. Gabapentin, in particular, is frequently used for off-label indications.
1 There has been controversy around the use of these drugs due to off-label marketing, 1 the short-term follow-up of studies, 2 potential for All adults (>17 years) in the MEPS were included. Gabapentinoid, benzodiazepine (including zolpidem tartrate and eszopiclone), and opioid prescriptions were identified. Medical conditions were identified by self-report, and an Elixhauser comorbidity index was calculated. Simple logistic regression was used to determine trends over time.
The OhioHealth Institutional Review Board considered the study exempt from review. All analyses were conducted using survey weighting in Stata, version 13 (StataCorp).
Results | The study included 346 177 adults between 2002 and 2015. The mean age of gabapentinoid users was 59.0 years (95% CI, 58.4-59.6 years) and 62.1% (95% CI, 60.3%-63.9%) of users were women. The percentage of individuals who used gabapentin and/or pregabalin increased from 1.2% (95% CI, 1.1%-1.4%) during a year in 2002 to 3.9% (95% CI, 3.6%-4.3%) in 2015 (trend, 1.10 odds ratio [OR] per year; 95% CI, 1.09-1.11; P < .001) (Figure 1) . Gabapentin was the predominantly used medication in the class, with 82.6% (95% CI, 81.0%-84.2%) of individuals. Prior to 2008, gabapentin use did not increase (OR per year, 1.02; 95% CI, 0.98-1.05; P = .39 for trend), but it increased after 2008 (OR, 1.12; 95% CI, 1.10-1.15; P < .001 for trend). Pregabalin use plateaued in 2008 and did not increase after that time (OR per year, 0.99; 95% CI, 0.95-1.03; P = .47 for trend).
There were increases in use among individuals older than 64 years ( Figure 2A ) and individuals with diabetes ( Figure 2B ). Additionally, there was increasing use of gabapentinoids in conjunction with increasing comorbidities (Figure 2C ), along with individuals who reported more than 2 opioid prescriptions and/or a benzodiazepine prescription ( Figure 2D ). In 2014 through 2015, 11.0% (95% CI, 10.5%-11.6%) of the population reported more than 2 opioid prescriptions or a benzodiazepine prescription and accounted for 52.6% (95% CI, 49.2%-56.0%) of gabapentinoid users.
Discussion | The use of gabapentinoids more than tripled between 2002 and 2015. A proportion of the increase was from the introduction of pregabalin, but more recently the increase has been from gabapentin. Importantly, the use of medications from the class was not evenly distributed through the population but concentrated among individuals who were older with numerous comorbidities and/or had numerous opioid prescriptions and/or had a benzodiazepine prescription.
The study had many limitations. Notably, medication use is self-reported and short-term medications, such as opioids, are likely underreported. Gabapentinoid expenditures could not be accurately reported due to high rebate levels for types of branded gabapentin.
The combination of a dearth of long-term safety data, small effect sizes, concern for increased risk of overdose in combination with opioid use, 4 and high rates of off-label prescribing, which are associated with high rates of adverse effects, raises concern about the levels of gabapentinoid use. While individual clinical scenarios can be challenging, caution should The figure identifies the proportion of gabapentinoid users among adults stratified by age (<65 vs Ն65 years), presence of diabetes, Elixhauser comorbidity index, and concomitant use of opioids (0-2 and Ն3 prescriptions) and benzodiazepines (any benzodiazepine prescription). be advised in the use of gabapentinoids, particularly for those
